Previous 10 |
Aptinyx ( APTX ) Q4 results : Revenues: $1M (-16.7%). More news on: Aptinyx Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Aptinyx (NASDAQ: APTX ): Q4 GAAP EPS of -$0.42 beats by $0.08 . More news on: Aptinyx Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Completed Phase 2 study of NYX-2925 in painful DPN -- did not meet primary endpoint, but NYX-2925 demonstrated robust analgesic activity in a large and mechanistically relevant patient sub-group Reported positive data from interim analysis of Phase 2 exploratory neuroimaging study of ...
EVANSTON, Ill., March 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webca...
Thinly traded micro cap Aptinyx (NASDAQ: APTX ) is down 9% premarket, albeit on only 195 shares, in sympathy with the selloff in Allergan after it announced a failed late-stage study of rapastinel in major depressive disorder (MDD). More news on: Aptinyx, Healthcare stocks ne...
Gainers: ALT +17.9% . HIIQ +9.7% . GWRE +8.1% . NGVC +7.0% . CMTL +7.0% . More news on: Altimmune, Inc., Health Insurance Innovations, Guidewire Software, Inc., Stocks on the move, Read more ...
EVANSTON, Ill., March 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present...
EVANSTON, Ill., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will particip...
Favorable safety and tolerability, linear pharmacokinetics, and ample CNS exposure of NYX-783 observed in Phase 1 Phase 2 data anticipated 1H 2020 EVANSTON, Ill., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing t...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...